Immunotherapy before surgery: which next step works best for lung cancer?

NCT ID NCT07166003

Recruiting now Knowledge-focused Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 500 lung cancer patients who received immunotherapy before their main treatment. Researchers want to see whether surgery (removing part or all of a lung) or non-surgery options like radiation lead to better long-term outcomes. The goal is to find the best approach after initial immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-tumor drugs (immunotherapy)
What this could lead to: If successful, this study could help doctors choose the best treatment after immunotherapy for lung cancer, potentially improving survival and reducing complications.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOTHERAPY LUNG CANCER (NON-SMALL CELL)

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.